Januvia 100mg Merckgroup
| Features | |
| Also known as | 7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine phosphate (1:1) |
| Blood pressure | Generally has a neutral effect on blood pressure |
| Chemical name | Sitagliptin phosphate |
| Dosage (medical) | Typically 100 mg once daily |
| Dosage (sports) | Not applicable |
| Effects | Improves blood glucose control |
| Formula | C16H15F6N5O•H3PO4 |
| Half-life | Approximately 12.4 hours |
| Hepatotoxicity | Low risk |
| Lab Test | Monitoring of blood glucose and HbA1c levels |
| Main action | Increases insulin release and decreases glucagon levels in a glucose-dependent manner |
| Raw Material | Sitaggliptin |
| Side effects | Nasopharyngitis, headache, upper respiratory tract infection, hypoglycemia (when used with other antidiabetics) |
| Storage conditions | Store at room temperature, away from moisture and heat |
| Substance class | Dipeptidyl peptidase-4 (DPP-4) inhibitor |
| Trade name | Januvia |
| Use in sports | Not typically used in sports |
| Water Retention | No significant effect |
| Manufacturer | MERCK |
| Packing | 28 tabs (100 mg/tab) |